PRGN-2009 is under clinical development by Precigen and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PRGN-2009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRGN-2009 is under development for the treatment of human papillomavirus (HPV positive) associated cancers such as esophageal cancer, lung cancer, vulvar cancer, rectal cancer and penile cancer, head and neck, cervical, vaginal, anal cancer and oropharyngeal cancer. It is administered through subcutaneous route. The therapeutic candidate is a vaccine that comprises of allogenic (off-the-shelf) adenoviral vectors and delivers HPV type 16 and HPV type 18 antigens through gorilla adenovector with a large genetic payload. It is developed based on the UltraVector and AdenoVerse technology platform.
Precigen is a clinical-stage biotechnology company that discovers, develops and commercializes next-generation gene and cell therapies to target diseases in immuno-oncology, autoimmune disorders and infections. The company’s clinical pipeline includes AG019, PRGN-3005, PRGN-3006, PRGN-3007, PRGN-2009 and PRGN-2012 for the indications of type 1 diabetes, ovarian cancer, acute myeloid leukemia and myelodysplastic syndromes, hematological and solid tumors, recurrent respiratory papillomatosis. Precigen preclinical pipeline includes PRGN-5001, PRGN-2010, PRGN-2011, PRGN-2013 and AG017, among others for solid tumors and celiac disease. The company utilizes therapeutic platforms including UltraCAR-T, AdenoVerse therapies, ActoBiotics, multifunctional therapeutics, UltraVector, AdenoVerse, AttSite, UltraPorator and RheoSwitch, among others. The compnay operates in the US and Belgium. Precigen is headquartered in Germantown, Maryland, the US.
For a complete picture of PRGN-2009’s drug-specific PTSR and LoA scores, buy the report here.